Agreement to explore Optimer vehicles for targeted delivery of siRNA

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce a new agreement with AstraZeneca, a global biopharmaceutical company, to evaluate the Optimer fibrotic liver delivery vehicles for the targeted delivery of siRNA.

Following the encouraging results achieved to-date with Aptamer’s fibrotic liver delivery vehicles, the next phase of this research will explore the potential of the non-viral delivery vehicle and its applicability with a tool siRNA.

Under the agreement, AstraZeneca will provide an siRNA to be trialled with Aptamer’s Optimer-based delivery vehicle for fibrotic liver cells. Aptamer Group will conduct in-house experimental work to assess the effectiveness of this delivery vehicle with the AstraZeneca’s siRNA. Upon success, Aptamer Group will progress to internally generating demonstrator data in animal models for evaluation by AstraZeneca.

Delivery of siRNA to precise cell types and tissues with successful cell internalisation remains a significant challenge for the wider therapeutic application of the technology.  Despite this limitation, the siRNA market was still valued at over $13 billion in 2023.

Optimer technology could represent a paradigm shift in the targeted delivery of siRNA molecules, due to the high levels of selectivity, high affinity and simple conjugation of siRNA payloads, offered using Optimer delivery systems as non-viral vectors.

If successful Optimer-enabled delivery of siRNA could lead to the development of novel compounds that have significant advantages over current cell and tissue-targeting methods. 

“We are really excited to work with AstraZeneca to evaluate and optimise our Optimer delivery vehicles. Partnerships such as this will enable Aptamer Group to make rapid progress in this area, which is a key focus for Optimer technology. Targeted delivery to specific cell types remains a critical unmet need in many applications within the tissue targeting space and, as such, has been part of our strategic focus to support the development of binders with the potential for long-term, high value. Our initial dataset in Optimer targeted delivery has raised significant interest from multiple parties. We are eager to advance to animal model testing and delighted to continue collaborating with AstraZeneca in this endeavour. Reaching proof of principle in animal models will derisk the Optimer delivery platform and bring us closer to delivering targeted and effective gene therapies for patients.”

Dr Arron Tolley, Chief Technical Officer of Aptamer Group


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Aptamer Group. (2024, July 09). Agreement to explore Optimer vehicles for targeted delivery of siRNA. News-Medical. Retrieved on July 21, 2024 from

  • MLA

    Aptamer Group. "Agreement to explore Optimer vehicles for targeted delivery of siRNA". News-Medical. 21 July 2024. <>.

  • Chicago

    Aptamer Group. "Agreement to explore Optimer vehicles for targeted delivery of siRNA". News-Medical. (accessed July 21, 2024).

  • Harvard

    Aptamer Group. 2024. Agreement to explore Optimer vehicles for targeted delivery of siRNA. News-Medical, viewed 21 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Top pharmaceutical company evaluates Optimer for precision liver medicine